Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Rogyo Kabushiki Kaisha

Shizuo Shiozaki

Junichi Shimada

Fumio Suzuki

Hiroshi Kase

Naoki Seno

Minoru Kobayashi

Akio Ishii

Shunji Ichikawa

Hiromi Nonaka

Joji Nakamura

Nobuaki Koike

Akihisa Mori

Katsuichi Shuto

Yoshihisa Kuwana

Shigeto Kitamura

Tomoyuki Kanda

Hironori Imma

Junya Kase

Hiroshi Sano

Yutaka Saito

Isao Kawamoto

Akira Karasawa

Kenji Ohmori

Tetsuji Ohno

Michio Ichimura

Haruhiko Manabe

Yoshimasa Oiji

Satoshi Nakanishi

Hiroshi Tsumuki

Tohru Yasuzawa

Hiromasa Kato

Akiko Nakamura

Naoto Osakada

Takako Kadowaki

Kazuihiro Kubo

Keiko Ohsawa

Katsuichi Shutoh

Takado Kadowaki

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine Areceptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine Areceptor antagonist.

Method of treating an anxiety disorder

Pharmaceutical composition

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine Areceptor antagonistic action, which is represented by the following formula (I): (wherein Rrepresents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, Rrepresents a hydrogen atom, or the like, Rrepresents &#x2014;WR, or the like, and Qrepresents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.

Agent for preventing and/or treating movement disorder

&lsqb;1,2,4&rsqb;triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives

&lsqb;1,2,4&rsqb;Triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A,receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A,receptors (for example, Parkinson's disease or senile dementia):

&lsqb;1,2,4&rsqb; triazolo &lsqb;1,5-C&rsqb; pyrimidine derivatives

Method of treating depression with certain triazine derivatives

Xanthine derivatives

Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl;

8-substituted styryl xanthine derivatives

Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.

Therapeutic agent for Parkinson's disease

A novel xanthine derivative of the formula (I): ##STR1## wherein one of R.sup.1 and R.sup.2 represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl; and the other represents

A xanthine derivative of the formula (I): ##STR1## wherein R.sup.1 represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl;

There are disclosed s-triazolo[3,4-i]purine derivatives represented by formula: ##STR1## wherein Y-Z represents ##STR2## R.sub.4 represents hydrogen, alkyl, substituted or unsubstituted aromatic heterocyclic group or substituted or unsubstituted aryl; and X.sup.2 represents oxygen, sulfur or NH; each of R.sup.1 and R.sup.2 independently represents hydrogen, alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; R.sup.3 represents alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; X.sup.1 represents oxygen or sulfur; and  represents a single bond or a double bond or pharmaceutically acceptable salts thereof.

s-Triazolo(3,4-I)purine derivatives

Growing community of inventors

Fuji, Japan

Shizuo Shiozaki